Shares of Atossa Genetics Inc (NASDAQ:ATOS) saw an uptick in trading volume on Thursday . 10,322,604 shares traded hands during mid-day trading, an increase of 718% from the previous session’s volume of 1,261,392 shares.The stock last traded at $1.70 and had previously closed at $1.49.
A number of brokerages have recently weighed in on ATOS. ValuEngine upgraded Atossa Genetics from a “hold” rating to a “buy” rating in a report on Monday. Maxim Group reiterated a “buy” rating and issued a $5.00 price target on shares of Atossa Genetics in a report on Wednesday, January 9th.
Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.01. As a group, equities analysts anticipate that Atossa Genetics Inc will post -5.13 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.com-unik.info/2019/02/07/atossa-genetics-atos-sees-large-volume-increase.html.
Atossa Genetics Company Profile (NASDAQ:ATOS)
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.